Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RVTY
HOLDRevvity, Inc. · Healthcare · United States · $12.3B · Avg Vol: $153M/d
COMPANY DESCRIPTION
Revvity, Inc. is a global life sciences and diagnostics company focused on improving human health through innovative technologies and services. The company provides a broad portfolio of instruments, reagents, software, and services for genomics, proteomics, cellular analysis, and diagnostics. Revvity holds a strong position in research and clinical markets due to its comprehensive solutions, strong R&D capabilities, and global reach, serving academic, pharmaceutical, and diagnostic customers.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.3B | 2.8B | 2.8B | 2.9B | -4.8% | 2.9B | 2.8B | 3.0B | 2.2% |
| EPS | 4.59 | 5.62 | 2.24 | 2.15 | -22.3% | 2.01 | 2.23 | 2.48 | 7.4% |
| Shares | 126.3M | 123.4M | 120.6M | 112.3M | -11.1% | 111.6M | — | — | — |
| Debt | 4.6B | 4.1B | 3.3B | 3.4B | -9.6% | 3.4B | — | — | — |
| Equity | 7.4B | 7.9B | 7.7B | 7.3B | -0.6% | — | — | — | — |
| Op CF | 679.8M | 91.3M | 628.3M | 582.9M | -5.0% | 570.0M | — | — | — |
| Inv CF | -132.9M | 1.3B | 776.2M | -17.4M | — | — | — | — | — |
| Fin CF | -661.8M | -947.1M | -1.1B | -857.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RVTY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RVTY | Revvity, Inc.(you) | $12.3B | 64 | HOLD |
| CRL | Charles River Laboratories International, Inc. | $10.9B | 69 | BUY |
| MEDP | Medpace Holdings, Inc. | $16.8B | 77 | BUY |
| SHC | Sotera Health Company | $4.9B | 66 | BUY |
| WAT | Waters Corporation | $36.8B | 65 | HOLD |
| GH | Guardant Health, Inc. | $19.5B | 47 | HOLD |
| IQV | IQVIA Holdings Inc. | $34.7B | 69 | BUY |
| IDXX | IDEXX Laboratories, Inc. | $42.9B | 60 | HOLD |
| A | Agilent Technologies, Inc. | $32.5B | 77 | BUY |
| NTRA | Natera, Inc. | $37.5B | 51 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%